United Therapeutics (NASDAQ:UTHR) Lifted to Hold at Jefferies Financial Group

Jefferies Financial Group upgraded shares of United Therapeutics (NASDAQ:UTHR) from an underperform rating to a hold rating in a research report report published on Thursday, BenzingaRatingsTable reports. The brokerage currently has $90.00 target price on the biotechnology company’s stock.

A number of other brokerages also recently commented on UTHR. Wedbush set a $273.00 price objective on shares of United Therapeutics and gave the company a buy rating in a research report on Wednesday, May 8th. Oppenheimer dropped their price objective on shares of United Therapeutics from $160.00 to $155.00 and set an outperform rating on the stock in a research report on Tuesday, April 9th. UBS Group raised shares of United Therapeutics from a sell rating to a neutral rating and dropped their price objective for the company from $115.00 to $94.00 in a research report on Friday, May 17th. They noted that the move was a valuation call. BidaskClub raised shares of United Therapeutics from a strong sell rating to a sell rating in a research report on Wednesday. Finally, ValuEngine downgraded shares of United Therapeutics from a hold rating to a sell rating in a research report on Tuesday, June 11th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $123.80.

UTHR traded up $0.19 during trading hours on Thursday, hitting $83.26. 445,907 shares of the company’s stock were exchanged, compared to its average volume of 559,204. United Therapeutics has a 12-month low of $74.31 and a 12-month high of $130.00. The stock’s 50 day moving average price is $78.16. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 6.22 and a beta of 1.05. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.84 and a current ratio of 4.62.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing the consensus estimate of $2.64 by ($13.96). United Therapeutics had a negative return on equity of 4.54% and a negative net margin of 7.69%. The business had revenue of $362.70 million for the quarter, compared to analysts’ expectations of $335.72 million. During the same period in the previous year, the company earned $3.76 earnings per share. United Therapeutics’s quarterly revenue was down 6.8% on a year-over-year basis. Analysts predict that United Therapeutics will post -3.9 earnings per share for the current fiscal year.

In other news, Director Raymond Dwek sold 3,750 shares of the company’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $76.11, for a total value of $285,412.50. Following the completion of the transaction, the director now owns 3,750 shares in the company, valued at approximately $285,412.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard Giltner sold 5,000 shares of the company’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $79.05, for a total transaction of $395,250.00. Following the completion of the transaction, the director now owns 5,000 shares of the company’s stock, valued at approximately $395,250. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Several institutional investors have recently modified their holdings of UTHR. Norges Bank acquired a new position in shares of United Therapeutics in the 4th quarter valued at $54,233,000. Pictet Asset Management Ltd. boosted its stake in United Therapeutics by 64.0% during the 1st quarter. Pictet Asset Management Ltd. now owns 266,163 shares of the biotechnology company’s stock worth $31,240,000 after purchasing an additional 103,840 shares during the period. First Trust Advisors LP boosted its stake in United Therapeutics by 7.8% during the 1st quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock worth $151,477,000 after purchasing an additional 93,786 shares during the period. Robeco Institutional Asset Management B.V. boosted its stake in United Therapeutics by 26.0% during the 1st quarter. Robeco Institutional Asset Management B.V. now owns 402,159 shares of the biotechnology company’s stock worth $47,204,000 after purchasing an additional 83,037 shares during the period. Finally, Virginia Retirement Systems ET AL boosted its stake in United Therapeutics by 154.6% during the 1st quarter. Virginia Retirement Systems ET AL now owns 108,200 shares of the biotechnology company’s stock worth $12,699,000 after purchasing an additional 65,700 shares during the period. Institutional investors and hedge funds own 95.37% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Recommended Story: What are convertible shares? 

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.